Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
8.23 ^USD	+3.52%		+0.12%	+124.86%

05-13	Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating	MT
05-08	Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024

MindMed Appoints Mgh Psychiatrist-In-Chief Dr. Maurizio Fava to Scientific Advisory Board

June 23, 2021 at 12:30 pm

MindMed has announced the addition of Dr. Maurizio Fava, expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company's Scientific Advisory Board.

Latest news about Mind Medicine (MindMed) Inc.

Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating	05-13	MT
Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target	04-15	MT
Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital	03-17	CI
RBC Raises Price Target on Mind Medicine (MindMed) to $22 From $15, Keeps Outperform, Speculative Risk	03-08	MT
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder	03-08	CI
Sector Update: Health Care Stocks Gain Late Afternoon	03-07	MT
Sector Update: Health Care Stocks Stronger in Afternoon Trading	03-07	MT
Roth MKM Raises Price Target on Mind Medicine to $36 From $25, Keeps Buy Rating	03-07	MT
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump	03-07	MT
Transcript : Mind Medicine Inc. - Special Call	03-07
Mind Medicine Inc. Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder	03-07	CI
Mind Medicine Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital	03-06	CI
RBC Lifts Price Target on Mind Medicine (MindMed) to $15 From $14, Notes Imminent Durability Data; Outperform, Speculative Risk Kept	02-29	MT
Transcript : Mind Medicine Inc., 2023 Earnings Call, Feb 28, 2024	02-28
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Mind Medicine Inc. Provides Anticipated Production Milestones for 2024	01-08	CI
Mind Medicine Says MM-120 Shows Significant Dose-Dependent Improvements in Phase 2b Trial on Anxiety Disorder	12-14	MT
Transcript : Mind Medicine Inc. - Special Call	12-14
Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder	12-14	CI
Transcript : Mind Medicine Inc., Q3 2023 Earnings Call, Nov 02, 2023	11-02
Mind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder	24/10/23	CI

Chart Mind Medicine (MindMed) Inc.

Duration

Period

More charts

Company Profile

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Sector

Biotechnology & Medical Research

Calendar

10/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.23 USD

Average target price

23.86 USD

Spread / Average Target

+189.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MIND MEDICINE (MINDMED) INC.	+124.86%	592M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research